GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (LSE:0JYO) » Definitions » Other Operating Expense

BB Biotech AG (LSE:0JYO) Other Operating Expense : €322.2 Mil (TTM As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is BB Biotech AG Other Operating Expense?

BB Biotech AG's Other Operating Expense for the three months ended in Mar. 2024 was €269.8 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was €322.2 Mil.

BB Biotech AG's quarterly Other Operating Expense increased from Sep. 2023 (€-50.4 Mil) to Dec. 2023 (€116.6 Mil) and increased from Dec. 2023 (€116.6 Mil) to Mar. 2024 (€269.8 Mil).

BB Biotech AG's annual Other Operating Expense increased from Dec. 2021 (€-387.8 Mil) to Dec. 2022 (€-361.4 Mil) and increased from Dec. 2022 (€-361.4 Mil) to Dec. 2023 (€-217.9 Mil).


BB Biotech AG Other Operating Expense Historical Data

The historical data trend for BB Biotech AG's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Other Operating Expense Chart

BB Biotech AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 621.66 640.64 -387.80 -361.40 -217.88

BB Biotech AG Quarterly Data
Sep16 Dec16 Mar17 Jun17 Dec17 Dec18 Dec19 Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -256.11 -13.80 -50.39 116.60 269.79

BB Biotech AG Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €322.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BB Biotech AG Other Operating Expense Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


BB Biotech AG (LSE:0JYO) Business Description

Traded in Other Exchanges
Address
Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.

BB Biotech AG (LSE:0JYO) Headlines

No Headlines